Q1 Earnings Estimate for IKT Issued By HC Wainwright

Inhibikase Therapeutics, Inc. (NYSE:IKT) – Investment analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for shares of Inhibikase Therapeutics in a research report issued on Wednesday, February 12th. HC Wainwright analyst E. White expects that the company will earn ($0.10) per share for the quarter. HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for Inhibikase Therapeutics’ current full-year earnings is ($0.97) per share. HC Wainwright also issued estimates for Inhibikase Therapeutics’ Q2 2025 earnings at ($0.11) EPS, Q3 2025 earnings at ($0.12) EPS, Q4 2025 earnings at ($0.13) EPS, FY2025 earnings at ($0.45) EPS and FY2026 earnings at ($0.56) EPS.

Separately, Jefferies Financial Group initiated coverage on Inhibikase Therapeutics in a report on Friday, November 8th. They set a “buy” rating and a $8.00 price target on the stock.

Inhibikase Therapeutics Price Performance

Shares of NYSE IKT opened at $2.60 on Monday. The stock’s 50-day moving average is $2.85 and its two-hundred day moving average is $2.20. Inhibikase Therapeutics has a 1-year low of $1.12 and a 1-year high of $4.20. The company has a market cap of $180.34 million, a price-to-earnings ratio of -0.97 and a beta of 1.06.

Institutional Investors Weigh In On Inhibikase Therapeutics

Several large investors have recently bought and sold shares of IKT. Soleus Capital Management L.P. purchased a new stake in Inhibikase Therapeutics during the 4th quarter worth about $20,556,000. Fairmount Funds Management LLC purchased a new position in shares of Inhibikase Therapeutics in the 4th quarter valued at about $19,906,000. ADAR1 Capital Management LLC purchased a new position in shares of Inhibikase Therapeutics in the 4th quarter valued at about $16,585,000. Nantahala Capital Management LLC purchased a new position in shares of Inhibikase Therapeutics in the 4th quarter valued at about $7,118,000. Finally, Blackstone Inc. purchased a new position in shares of Inhibikase Therapeutics in the 4th quarter valued at about $6,730,000. Hedge funds and other institutional investors own 3.81% of the company’s stock.

Inhibikase Therapeutics Company Profile

Inhibikase Therapeutics, Inc, a clinical-stage pharmaceutical company, develops therapeutics for Parkinson’s disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson’s disease and gastrointestinal tract.